7 Best Peptides for Egg Quality

What to Know Before Choosing a Peptide for Egg Quality

Egg quality is one of the most searched and most contested topics in reproductive optimization. The question is specific: not fertility in general, but whether the eggs themselves, their chromosomal integrity, their mitochondrial health, their ability to complete meiosis and support a viable embryo, can be meaningfully influenced before or during an IVF cycle, or while trying to conceive naturally. That question has drawn serious research attention, particularly for women over 35, where oocyte aging is the primary driver of declining fertility outcomes.

The peptides covered here earned a slot for a single reason: people are using them for egg quality, or are actively discussing doing so. That pool spans a wide range. Kisspeptin is used in clinical IVF protocols. Sermorelin is prescribed through telemedicine. The FEE peptide is in a Phase 3 clinical trial. MOTS-c and SS-31 are research-only compounds with a strong biological rationale and growing community use but limited human trial data. Zhenoluten is a Russian peptide bioregulator with a following in certain fertility communities and a thinner Western evidence base. All of them belong here, and the evidence for each is described honestly rather than used as a reason to include or exclude.

No peptide is FDA-approved specifically for improving egg quality, and the evidence varies considerably from compound to compound. That reality is stated once here so it does not have to be repeated in every entry. Where a compound has solid human trial data, that is noted directly. Where the evidence is animal-model only or community-reported, that is also stated plainly.

The numbering reflects how prominently each compound appears in research and real-world use for egg quality, not a recommendation of one over another. The right choice depends on your specific situation, your stage in a fertility journey, and factors that a personalized plan should address.

1. Sermorelin and Ipamorelin: Supporting the Hormonal Axis That Drives Follicle Development

Sermorelin is a 29-amino acid synthetic analog of growth hormone-releasing hormone, the signal your hypothalamus sends to tell the pituitary to produce and release growth hormone. Ipamorelin is a 5-amino acid growth hormone-releasing peptide that works through a parallel receptor to achieve a similar outcome. They are often used together because their mechanisms complement each other, producing a more sustained rise in growth hormone than either one alone.

The connection to egg quality runs through IGF-1, insulin-like growth factor 1, a downstream messenger that rises when growth hormone levels increase. IGF-1 has well-characterized roles in follicle development: it drives granulosa cell proliferation, granulosa cells being the support cells that surround and nourish each developing egg; it supports the hormonal signaling within the follicle; and it is associated with reduced rates of chromosomal abnormalities in maturing oocytes. In clinical assessments of women using growth hormone secretagogues in the months before an IVF cycle, some studies have found roughly 20 percent fewer aneuploid embryos, meaning embryos with the wrong chromosome count, compared to women who did not use them. IGF-1 elevation in the 40 to 60 percent range has been reported with this class of compounds.

Sermorelin specifically has an approved history in the US, having been FDA-approved for growth hormone deficiency in children before that approval was withdrawn for commercial reasons. It continues to be legally compounded by licensed US pharmacies and is available through telemedicine platforms that work with compounding pharmacies. That accessibility is part of why it appears so frequently in functional medicine fertility protocols. Ipamorelin is less formally approved but is widely used alongside Sermorelin in the same contexts.

The evidence is promising but not definitive. The 20-percent-fewer-aneuploid-embryos figure comes from small human studies and clinical observations rather than large randomized controlled trials specifically designed to test this outcome. What exists is directionally consistent and biologically well-grounded. Used off-label under physician supervision, this pairing is among the more clinically reasonable options on this list.

2. The FEE Peptide: The Only Compound With Direct Human Evidence for Chromosomal Quality

The FEE peptide is a cyclic peptide derived from fertilin, a protein involved in the biology of egg-sperm interaction. It was developed through roughly 30 years of research at Institut Cochin in Paris and is the subject of an active Phase 3 clinical trial. It is the only compound on this list with direct published human evidence for improving chromosomal quality in oocytes.

The evidence behind it is specific and striking. In a published in vitro study involving more than 1,600 human oocytes, the FEE peptide improved maturation rates by approximately 30 percent compared to controls. More importantly, it reduced chromosomal segregation errors during meiosis I, the cell division stage where chromosomal mistakes most commonly occur in aging eggs, and increased the euploidy rate, meaning a higher proportion of eggs ended up with the correct 23 chromosomes. In IVF protocols where it was applied, the birth rate increased by 7 to 13 percent. A Phase 3 clinical trial enrolling 360 couples, promoted by the Paris public hospital system, is currently underway with results expected to support a marketing authorization application.

The practical reality is that the FEE peptide is not yet commercially available for individual use. It exists in a research and clinical trial context. Its position in this guide reflects the fact that it has the most direct human evidence for improving the thing that matters most in egg quality, chromosomal integrity, which is why fertility researchers and fertility-focused communities track it closely. For someone weighing their options and watching the space, the FEE peptide is the compound where the published data is most precisely targeted at the problem itself.

3. Kisspeptin-10: Hormonal Signaling for Follicle Development and IVF Triggering

Kisspeptin is a family of neuropeptides derived from the KISS1 gene. Kisspeptin-10 is the shortest bioactive fragment, a 10-amino acid sequence that retains full receptor binding activity at the KISS1R receptor. The longer form, Kisspeptin-54, is the variant used in most clinical IVF trials, but Kisspeptin-10 is the form most frequently discussed in fertility optimization communities and research contexts.

The mechanism works upstream in the reproductive hormone cascade. Kisspeptin binds to KISS1R receptors on GnRH neurons in the hypothalamus, increasing the frequency of GnRH pulses. More GnRH pulses mean more FSH and LH released by the pituitary. FSH, follicle-stimulating hormone, drives follicle development and oocyte maturation. LH, luteinizing hormone, triggers the final maturation and ovulation. Kisspeptin also upregulates FSH receptors on granulosa cells, which makes follicles more responsive to hormonal signals they are already receiving.

The clinical evidence for kisspeptin is genuine and specific. Phase 1 and Phase 2 clinical trials have been completed using Kisspeptin-54 as an ovulation trigger in IVF, with 73 healthy babies born across those trials. The primary finding is not that kisspeptin improves egg chromosomal quality per se, but that it provides a safer alternative to the standard hCG trigger shot. Ovarian hyperstimulation syndrome, a potentially serious complication of IVF, occurs at significantly lower rates when kisspeptin is used as the trigger. For women at elevated OHSS risk, this is a meaningful clinical advantage.

Kisspeptin-10 specifically appears primarily in community discussions about promoting egg health and follicle development before an IVF cycle. No clinical data exists confirming measurable egg quality improvements from self-administered Kisspeptin-10 outside a formal IVF protocol. What exists in the community is exploratory interest and anecdotal use alongside other compounds. The broader kisspeptin evidence base from clinical trials gives this compound genuine credibility in the fertility space, even where the shorter fragment's individual evidence is more limited.

4. Epitalon: Antioxidant and Telomere Support for Aging Oocytes

Epitalon is a synthetic tetrapeptide, four amino acids (Ala-Glu-Asp-Gly), derived from epithalamin, a natural extract from the pineal gland. It was developed by Vladimir Khavinson's research group at the St. Petersburg Institute of Bioregulation and Gerontology and has been studied primarily as an anti-aging compound.

Its relevance to egg quality is indirect but biologically grounded. Egg cells age, and as they do, their mitochondrial membranes become more vulnerable to oxidative damage, their telomeres shorten, and their DNA repair capacity declines. These are the same cellular aging mechanisms that affect other tissues, and they are a primary reason why oocyte quality in women over 35 declines faster than simple hormone levels would suggest. Epitalon addresses this through several pathways: it activates telomerase, the enzyme that maintains telomere length; it stimulates melatonin production, which has direct antioxidant effects on ovarian tissue; and it is associated with reduced oxidative stress markers in cellular aging research. Animal studies have shown improvements in oocyte quality markers in aging ovarian tissue, and early human data is consistent with favorable effects on cellular aging processes in relevant tissue types.

The honest framing is that Epitalon's egg quality application extrapolates from its anti-aging mechanisms. There are no large-scale randomized controlled trials in humans specifically measuring oocyte quality as the primary endpoint. What exists is a combination of animal model findings, early human data on cellular aging markers, and a coherent biological rationale for why reducing oxidative stress and supporting telomere maintenance in ovarian tissue would benefit oocyte health in older women. That is a stronger foundation than pure community use, but it is not the same as dedicated clinical trial evidence. Epitalon is most consistently discussed for women over 35 whose primary egg quality challenge is the accumulated burden of cellular aging rather than an acute hormonal issue.

5. MOTS-c: Mitochondrial Energy for Oocyte Viability

MOTS-c is a 16-amino acid peptide encoded not in the nuclear genome but in the mitochondrial genome, specifically in the 12S rRNA region. That origin is significant. Mitochondria, the energy-producing structures inside cells, generate their own peptide signals that regulate how the body manages energy at the cellular level. MOTS-c is one of those signals, characterized as a metabolic regulator that activates AMPK signaling, a pathway that shifts cells from energy storage toward energy production, in a way that resembles some effects of aerobic exercise at the cellular level.

The relevance to egg quality is direct. Egg cells contain an extraordinary number of mitochondria, in the range of hundreds of thousands per cell, far more than most other cell types. The reason is that completing meiosis, the specialized cell division that produces a viable egg with the correct 23 chromosomes, is energetically expensive. ATP production in the oocyte's mitochondria is one of the critical factors determining whether meiosis completes correctly and whether the resulting egg can be fertilized and develop into a viable embryo. Mitochondrial dysfunction in aging oocytes, declining membrane potential and reduced ATP output, is a well-established contributor to the chromosomal segregation errors that make eggs less viable with age. MOTS-c's mechanism addresses this directly by enhancing mitochondrial bioenergetics.

No human clinical trial data has been published for MOTS-c in egg quality as of 2026. What exists is animal and in vitro evidence for its mitochondrial effects, alongside a growing body of community-reported use among women undergoing IVF who are pursuing aggressive pre-cycle protocols. Active discussions on fertility and peptide forums reflect genuine interest and real-world use, with users consistently acknowledging the absence of established clinical evidence. The biological rationale is among the strongest for any compound on this list. The human evidence for egg quality outcomes specifically remains experiential.

6. SS-31: Targeted Mitochondrial Protection at the Membrane Level

SS-31, also known in clinical development contexts as elamipretide, is a 4-amino acid synthetic peptide with a highly specific mechanism. Unlike compounds that support mitochondrial function broadly, SS-31 concentrates selectively in the inner mitochondrial membrane, the site where ATP is actually produced. There it protects cardiolipin, a phospholipid that is critical to mitochondrial membrane integrity and to the electron transport chain function that drives ATP synthesis. By protecting cardiolipin from oxidative damage, SS-31 maintains membrane potential and preserves ATP output under conditions of oxidative stress.

For aging oocytes, this specificity matters. The mitochondrial dysfunction that accumulates in eggs as women age is concentrated at the membrane level, in declining potential and oxidized structural lipids. SS-31 was developed to address exactly that failure point. In rodent studies, SS-31 has shown effects on mitochondrial function in oocytes that compare favorably with coenzyme Q10, the mainstream supplement recommendation for egg quality support, and some early human data is consistent with those findings.

In practice, SS-31 is most often used alongside MOTS-c as a combined mitochondrial support approach for women preparing for IVF. Community discussions on fertility and peptide forums track this combination actively. SS-31 is a research-only compound with no human clinical trials for fertility use. Its clinical development pathway has focused on cardiac applications, not reproductive ones. Individual reports in the community are mixed: some users describe increased energy shortly after starting SS-31, while others report no measurable fertility benefit from their cycle. The evidence base is experiential rather than clinical, set against a genuinely strong biological rationale for its mechanism in aging oocytes.

7. Zhenoluten: The Ovarian Bioregulator From Russian Research

Zhenoluten is a peptide bioregulator developed within the Russian research tradition associated with Vladimir Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology. It is derived from ovarian tissue and belongs to a class of compounds called cytamines, short peptides extracted from specific organs that are theorized to support the same organ type in the recipient. Similar bioregulators from this research program include Epitalon for the pineal gland and Cortagen for the brain.

The proposed mechanism is that Zhenoluten's peptides, once absorbed, interact with DNA in the promoter regions of ovarian cells and regulate gene expression related to ovarian cell function, folliculogenesis, and hormonal production. The broader Khavinson bioregulator framework holds that these short peptides act as epigenetic regulators, switching on cellular maintenance and repair programs that become downregulated with age. Ovarian reserve support and improved follicle development are the primary claims associated with Zhenoluten in the communities where it is discussed.

No human clinical trial data from large-scale, Western peer-reviewed studies has been published specifically for Zhenoluten as of 2026. The evidence draws from the Russian clinical literature on peptide bioregulators, which has produced published studies but with limited replication outside that tradition. In fertility optimization communities and functional medicine circles, Zhenoluten appears in discussions about female reproductive support, often as part of broader bioregulator protocols. It is available in oral capsule form from European supplement retailers and some international online sources, though its status varies by country and it is not FDA-approved. Anyone considering it should approach it with the context of its limited and geographically narrow evidence base clearly in mind.

How These Peptides Compare

Frequently Asked Questions

Are these peptides legal to use for egg quality?

The answer varies by compound. Sermorelin is legally compounded by licensed US pharmacies and can be prescribed through telemedicine platforms. Kisspeptin is used in clinical IVF settings but is not FDA-approved for individual self-administration. The FEE peptide is currently only available through a clinical trial context. MOTS-c, SS-31, and Epitalon are sold as research chemicals in jurisdictions where that designation applies, and Zhenoluten's regulatory status depends on the country. None of these compounds is FDA-approved specifically for improving egg quality, and the regulatory landscape for research peptides is actively evolving.

How long before these compounds would show any effect on egg quality?

Egg development cycles take roughly 90 days from the time a follicle begins its final maturation to retrieval or ovulation, which is why most fertility optimization protocols are designed to run for at least three months before a planned retrieval or conception attempt. The commonly cited window in functional medicine and IVF contexts is three to six months of consistent use before a cycle. That framing is based on the biology of folliculogenesis rather than on standardized clinical trial endpoints for any of these specific peptides, so it is a reasonable starting point rather than a confirmed promise.

Do you need a doctor to use these compounds?

For compounds like Sermorelin that are available through legitimate medical channels, a prescription and physician oversight are part of the process. For research chemicals like MOTS-c, SS-31, and Zhenoluten, no prescription is required to obtain them, but the absence of a prescription requirement does not remove the importance of medical guidance. Using any compound intended to influence reproductive hormones or oocyte development without the knowledge of a reproductive endocrinologist or fertility specialist carries real risks, both for safety and for avoiding interference with a formal IVF protocol. Anyone pursuing these compounds in the context of active fertility treatment should be transparent with their clinical team.

Is there anything with direct evidence for improving chromosomal quality in eggs?

The FEE peptide has the most direct published human evidence for this specific outcome. Its in vitro study of more than 1,600 oocytes showed improvements in chromosomal segregation during meiosis I and a higher euploidy rate, and a Phase 3 clinical trial is currently underway. Growth hormone secretagogues like Sermorelin and Ipamorelin have also been associated with reduced aneuploidy rates in small human studies. Everything else on this list influences the broader cellular environment of oocyte health through mitochondrial function, oxidative stress, or hormonal signaling, rather than chromosomal quality directly.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and real-world use of peptides for egg quality in one place.